Bibliography

Research using CPRD data has informed drug safety guidance and clinical practice and resulted in over 2,700 peer-reviewed publications. The CPRD bibliography is updated on a monthly basis (last updated 6 April 2021) and papers are listed below and in the PDF below.

If you have published papers using CPRD data which are not included in this list, please contact us at enquiries@cprd.com so that we can update the bibliography.

Download:

 (PDF, 5MB, 226 pages) 

This work uses data provided by patients and collected by the NHS as part of their care and support. CPRD encourages researchers to use this citation in all publications using CPRD data. Find out more about acknowledging the use of patient data at the Understanding Patient Data website

 

 

Export 12 results:
Author Title [ Type(Asc)] Year
Filters: Author is Douros, A.  [Clear All Filters]
Journal Article
A. Douros, Abrahami, D., Yin, H., Yu, O. H. Y., Renoux, C., Hudson, M., and Azoulay, L., Use of Dipeptidyl Peptidase-4 Inhibitors and New-onset Rheumatoid Arthritis in Patients with Type 2 Diabetes, Epidemiology, vol. 29, pp. 904-912, 2018.
A. Douros, Dell'Aniello, S., Yu, O. H. Y., Filion, K. B., Azoulay, L., and Suissa, S., Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: population based cohort study, Bmj, vol. 362, p. k2693, 2018.
K. B. Filion, Douros, A., Azoulay, L., Yin, H., Yu, O. H., and Suissa, S., Sulfonylureas as initial treatment for type 2 diabetes and the risk of adverse cardiovascular events: A population-based cohort study, Br J Clin Pharmacol, 2019.
D. Abrahami, Douros, A., Yin, H., Yu, O. H. Y., and Azoulay, L., Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of Fractures Among Patients With Type 2 Diabetes, Diabetes Care, vol. 42, pp. e150-e152, 2019.
A. Douros, Yin, H., Yu, O. H. Y., Filion, K. B., Azoulay, L., and Suissa, S., Pharmacologic Differences of Sulfonylureas and the Risk of Adverse Cardiovascular and Hypoglycemic Events, Diabetes Care, vol. 40, pp. 1506-1513, 2017.
A. Douros, Santella, C., Dell'Aniello, S., Azoulay, L., Renoux, C., Suissa, S., and Brassard, P., Infectious Disease Burden and the Risk of Alzheimer's Disease: A Population-Based Study, J Alzheimers Dis, 2021.
D. Abrahami, Douros, A., Yin, H., Yu, O. H., Faillie, J. L., Montastruc, F., Platt, R. W., Bouganim, N., and Azoulay, L., Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study, Bmj, vol. 363, p. k4880, 2018.
A. Douros, Filion, K. B., Yin, H., Yu, O. H., Etminan, M., Udell, J. A., and Azoulay, L., Glucagon-Like Peptide 1 Receptor Agonists and the Risk of Incident Diabetic Retinopathy, Diabetes Care, vol. 41, pp. 2330-2338, 2018.
A. Douros, Rouette, J., Yin, H., Yu, O. H. Y., Filion, K. B., and Azoulay, L., Dipeptidyl Peptidase-4 Inhibitors and the Risk of Bullous Pemphigoid Among Patients With Type 2 Diabetes, Diabetes Care, 2019.
D. Abrahami, Douros, A., Yin, H., Yu, O. H. Y., Renoux, C., Bitton, A., and Azoulay, L., Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study, Bmj, vol. 360, p. k872, 2018.
A. Douros, Dell'Aniello, S., Dehghan, G., Boivin, J. F., and Renoux, C., Degree of serotonin reuptake inhibition of antidepressants and ischemic risk: A cohort study, Neurology, vol. 93, pp. e1010-e1020, 2019.
A. Douros, Dell'Aniello, S., Yu, O. H. Y., and Suissa, S., Comparative cardiovascular and hypoglycemic safety of glimepiride in type 2 diabetes: A population-based cohort study, Diabetes Obes Metab, 2019.
[Page last reviewed 6 April 2021]